Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18498621 | 0.89 | LMNA (0.56) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL3652385 | 0.86 | LMNA (0.54) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL3708900 | 0.86 | LMNA (0.54) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL3652388 | 0.86 | LMNA (0.54) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL29838433 | 0.86 | LMNA (0.47) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL20912047 | 0.85 | POLB (0.56) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL3652718 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL3649934 | 0.84 | POLB (0.51) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL3649936 | 0.84 | POLB (0.51) | LMNASMN1; SMN2POLBGBA2ALDH1A1 | |
| SCHEMBL30497646 | 0.84 | POLB (0.51) | LMNASMN1; SMN2POLBGBA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4429663-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4419207-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023224893-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H BIOTECH INC. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4212522-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | J2H Biotech Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023086799-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023067354-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-4166555-A1 | PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| EP-3728252-A1 | 4-AZAINDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-101466726-B | Azacyclo derivatives of androstanes and androstenes as medicaments for the treatment of cardiovascular disorders | SIGMA TAU IND FARMACEUTI | 2014-09-24 | — | — | CN | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| CN-101466726-A | Azacyclo derivatives of androstanes and androstenes as medicaments for the treatment of cardiovascular disorders | SIGMA TAU IND FARMACEUTI (IT) | 2009-06-24 | — | — | CN | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| CN-1173972-C | Azacycloether derivatives and their use as nicotinic acetylcholine receptor modulators | О | 2004-11-03 | — | — | CN | disclosed |
| CN-1278258-A | Azacycloether derivatives and their use as nicotinic acetylcholine receptor modulators | NEUROSEARCH AS (DK) | 2000-12-27 | — | — | CN | disclosed |
| EP-0500835-A1 | A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE. | DAE WOONG PHARMA (KR) | 1992-09-02 | — | — | EP | disclosed |
| WO-1992004342-A1 | A NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322723-A1 | COMPOUNDS FOR SUPPRESSING EGFR MUTANT CANCER AND PHARMACEUTICAL USE THEREOF | EGFR, KRAS, ERBB2 | LMNA 4456/4885SMN1; SMN2 4518/4885POLB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.